Transcranial Direct Current Stimulation in Post-Acute COVID-19 Patients With Systemic Autoimmune Rheumatic Diseases

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Some patients develop Post-acute COVID-19 syndrome, in which they experience persistent symptoms after recovering from the acute phase of COVID-19 infection. This syndrome may be more significant in patients with systemic autoimmune rheumatic diseases (SARDs) who have been suffering from several symptoms associated to SARDs, such as myalgia, fatigue, and general pains. The transcranial direct current stimulation (tDCS) technique has been frequent, for example, to relieve fatigue and general pains in general population. However, to date, there are no studies evaluating this technique in ARD patients with post-acute COVID-19; therefore, the main objective of the opened study is to evaluate the safety and efficacy of the application of acute tDCS in ARD patients with post-acute COVID-19.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Patients with well-defined ARDs (rheumatoid arthritis, sclerosis systemic, Sjögren syndrome, spondyloarthritis, systemic lupus erythematosus, systemic vasculitis, and systemic autoimmune myopathies)

• Fatigue or general pains.

Locations
Other Locations
Brazil
Samuel K Shinjo
RECRUITING
São Paulo
Contact Information
Primary
Samuel K Shinjo, PhD
samuel.shinjo@usp.br
551130617176
Time Frame
Start Date: 2021-05-17
Estimated Completion Date: 2024-12-04
Participants
Target number of participants: 20
Treatments
Experimental: Intervention
The ARD patients with post-acute COVID-19 will receive tDCS sessions for one week.
Related Therapeutic Areas
Sponsors
Leads: University of Sao Paulo

This content was sourced from clinicaltrials.gov